SNBP - Sun BioPharma, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Sun BioPharma, Inc.

712 Vista Boulevard
Suite 305
Waconia, MN 55387
United States
952-479-1196
http://www.sunbiopharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Dr. Michael T. Cullen Jr.Co-Founder, Exec. Chairman, Pres & CEO221.2kN/A1946
Ms. Susan HorvathVP of Fin., CFO, Sec. & Treasurer213kN/A1959
Dr. Thomas X. NeenanCo-Founder & Chief Scientific OfficerN/AN/AN/A
Ms. Tammy GroeneVP of OperationsN/AN/AN/A
Dr. Suzanne GagnonChief Medical Officer & DirectorN/AN/A1957
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sun BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics treatment for unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase 1a/1b clinical trial for the treatment of patients with pancreatic cancer. The company has scientific collaborations with pancreatic disease experts Cedars Sinai Medical Center in Los Angeles, the University of Miami; the University of Florida; the Austin Health Cancer Trials Centre in Melbourne, Australia; the Ashford Cancer Centre in Adelaide, Australia; and the Blacktown Cancer and Haematology Centre in Sydney, Australia. Sun BioPharma, Inc. was founded in 2011 and is based in Waconia, Minnesota.

Corporate Governance

Sun BioPharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.